aortic valve replacement

TCT 2020 | Eficacia del dispositivo de protección cerebral TriGUARD 3 durante el TAVI

TCT 2020 | Efficacy of Cerebral Protection Device TriGUARD 3 During TAVR

Cerebral protection device TriGUARD&nbsp;3, designed to cover all supra-aortic vessels during transcatheter aortic valve replacement (TAVR), is safe to use, according to the outcomes of the REFLECT&nbsp;II study. The technical feasibility of the device, which requires transfemoral access, does not seem to have an impact over clinical events. The primary safety endpoint was a VARC-2-defined<a href="https://solaci.org/en/2020/10/21/tct-2020-efficacy-of-cerebral-protection-device-triguard-3-during-tavr/" title="Read more" >...</a>

The Most Read Articles of September in Interventional Cardiology

01- ESC 2020 | New European Guidelines on Non-ST-Segment Elevation Acute Coronary Syndromes: What’s New? The new European guidelines on NON-ST-segment elevation acute coronary syndromes (NSTE ACS) were presented virtually during the European Society of Cardiology 2020 Congress (ESC&nbsp;2020) and published in&nbsp;Eur Heart J. Read more HERE 02- Ticagrelor to Improve Venous Graft Patency Saphenous<a href="https://solaci.org/en/2020/10/09/the-most-read-articles-of-september-in-interventional-cardiology/" title="Read more" >...</a>

Death, Stroke, and Hospitalization while Waiting for TAVR

The consequences of deferring transcatheter aortic valve replacement (TAVR) procedures because of the COVID 19 pandemic are piling up. Untreated severe aortic stenosis patients who had been scheduled for TAVR are seeing increased risk of all events, even mortality.&nbsp; According to recent studies published in JAMA, deferring TAVR in patients with symptomatic aortic stenosis is<a href="https://solaci.org/en/2020/10/08/death-stroke-and-hospitalization-while-waiting-for-tavr/" title="Read more" >...</a>

Post TAVR ASA Monotherapy Consolidates

This meta-analysis to be published in J Am Cardiol supports the use of aspirin monotherapy (ASA) after transcatheter aortic valve replacement (TAVR). The use of aspirin alone is associated to less bleeding without increased ischemic events such as strokes or mortality.&nbsp; The combined outcomes of four studies, including the recently published POPular TAVI (cohort A),<a href="https://solaci.org/en/2020/10/07/post-tavr-asa-monotherapy-consolidates/" title="Read more" >...</a>

TAVR via trans-carotidea anestesia local o general

Minimalist TAVR to the Max

Transcatheter aortic valve replacement (TAVR) is increasingly being performed under conscious sedation, which is associated with a multi-point benefit (including mortality).  This paper, recently published in JACC Intv., shows that general anesthesia is becoming obsolete, although the magnitude the benefit derived from conscious sedation appears to be lower than in previous studies. The aim of<a href="https://solaci.org/en/2020/10/02/minimalist-tavr-to-the-max/" title="Read more" >...</a>

valve_in_valve

Size Does Matter for Long Term ViV

The size of the original bioprosthetic valve impacts long term mortality, as does the type of bioprosthetic valve used in percutaneous reinterventions.  The number of patients with failed bioprosthesis is on the rise, mainly due to increased life expectancy.  Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has become more and more common these days and<a href="https://solaci.org/en/2020/09/29/size-does-matter-for-long-term-viv/" title="Read more" >...</a>

TAVI bajo riesgo

TAVR as Anti-Inflammatory? An effect few imagined

We never saw it coming, such a pleiotropic effect: who would have though a mechanical device could have such a systemic anti-inflammatory effect? Transcatheter aortic valve replacement (TAVR) does in fact have it.  The shear stress aortic stenosis produces activates multiple inflammatory responses mediated by monocytes. This study identified the most important mechanoreceptor, involved in<a href="https://solaci.org/en/2020/09/28/tavr-as-anti-inflammatory-an-effect-few-imagined/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Considerations for Optimal Device Selection in TAVR

Many studies have tried to answer the question about whether there is a superior device in transcatheter aortic valve replacement (TAVR). Today, there is no evidence to support such claim, and most patients will likely find operator experience more beneficial than any device per se.&nbsp;&nbsp; However, there are certain patients with specific characteristics that might<a href="https://solaci.org/en/2020/09/24/considerations-for-optimal-device-selection-in-tavr/" title="Read more" >...</a>

Trombólisis local en tromboembolismo pulmonar

TAVR After Endocarditis? Contraindication or Last Resort

Transcatheter aortic valve replacement (TAVR) can be an alternative for aortic valves with endocarditis successfully treated with antibiotics, which no longer are severe valve lesions. At one year, the risk of endocarditis relapse was low and the mortality rate was similar to that of patients without a history of infection. This aim of this study<a href="https://solaci.org/en/2020/09/22/tavr-after-endocarditis-contraindication-or-last-resort/" title="Read more" >...</a>

Una nueva molécula para evitar la nefropatía por contraste

Same Contrast Dose, Different Risk of Kidney Injury, Depending on Procedure

The risk of contrast induced kidney injury is significantly lower in patients receiving transcatheter aortic valve replacement (TAVR) compared against patients getting a coronary angiography or angioplasty.&nbsp; This is true even for valvular heart disease patients with higher risk profiles.&nbsp; Differences in contrast-induced acute kidney injury between TAVR or coronary patients had not been previously<a href="https://solaci.org/en/2020/09/16/same-contrast-dose-different-risk-of-kidney-injury-depending-on-procedure/" title="Read more" >...</a>

Top